Summit Therapeutics Inc.

Summit ended Q2 2026 with approximately $690.7 million in cash, up from $598.7 million at the end of Q1 2026. The quarter’s increase in cash was driven mainly by $231 million raised from the ATM facility, offset by about $140 million of operating cash use. Total GAAP operating expenses were $220.5 million in Q2 2026 versus $195.2 million in Q1 2026; non-GAAP operating expenses were $151.8 million versus $122.4 million. Management did not give revenue or EPS figures on the call. For guidance, Summit said the HARMONi BLA remains under FDA review with a target PDUFA date of November 14, expects HARMONi-3 squamous PFS data in the second half of 2026, and expects the next independent OS look in the first half of 2027. It also said the GSK collaboration should enroll its first patient later this quarter and the Arcus combo should generate initial data by mid next year.

Bob Duggan framed ivonescimab as Summit’s core platform asset and emphasized that the drug now has four Phase III readouts, all positive, plus two approvals in China and a pending U.S. BLA. His tone was highly optimistic and strategic, stressing broad interest from big pharma, a growing clinical footprint, and the potential to use ivonescimab across multiple solid tumors and combinations. He repeatedly described the opportunity as platform-like and said the company is preparing for commercialization ahead of a possible FDA decision later this year.

Manmeet Soni focused on liquidity, expense growth, and launch readiness. He said cash finished the quarter at approximately $690.7 million, with the increase from Q1 primarily reflecting $231 million raised via ATM and roughly $140 million used in operations; he also noted the company filed a new ATM prospectus supplement for up to $380 million and has no debt. GAAP operating expenses rose to $220.5 million from $195.2 million, and non-GAAP operating expenses increased to $151.8 million from $122.4 million, mostly because of higher R&D tied to HARMONi-GI3, HARMONi-3, and HARMONi-7. He also said commercial leadership is in place, market access and marketing teams are built, and MSLs have been ramped up for a potential launch.

Analysts pressed management on whether the updated HARMONi OS data should translate to frontline settings like HARMONi-3, and management said the key variable is follow-up time, not region alone. They also asked whether the delayed HARMONi-3 readout implies weaker performance; management said the study was fully global from the start, enrollment timing differed by region, and the earlier interim had limited follow-up and a higher significance bar. Several questions focused on OS timing, alpha spend, and whether the new HARMONi analysis could affect the November 14 PDUFA date; management said the PDUFA timing is up to the FDA, the interim OS looks are formal analyses, and the alpha spend for the early supportive look is minimal. There was also a competitive question about amivantamab and TROP-2 ADCs, and management argued ivonescimab’s differentiator is its mechanism plus a manageable safety profile and the possibility that different patients respond to different drugs.